<DOC>
	<DOCNO>NCT00833664</DOCNO>
	<brief_summary>The Purpose study o evaluate relative bioavailability test formulation terbinafine tablet already market reference formulation LamisilÂ® ( Novartis Pharmaceuticals ) , post-prandial condition healthy , non-tobacco use male female adult subject .</brief_summary>
	<brief_title>Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Males female , 18 year older inclusive body mass index ( BMI ) 30 less . Good health determine lack clinically significant abnormality health assessment perform screen . Signed date informed consent form , meet criteria current FDA regulation If female child bear potential subject must prepare abstain sexual intercourse use reliable barrier method contraception ( e.g . condom , IUD ) duration study . Female subject use oral contraceptive within 14 day inject hormonal contraceptive within 180 day dose allowed participate . If female , pregnant , lactate likely become pregnant study . History allergy sensitivity terbinafine , history drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study . Significant history current evidence chronic evidence chronic infectious disease , system disorder ot organ dysfunction . Presence gastrointestinal disease ot history malabsorption within last year . History psychiatric disorder occur within last two year require hospitalization medication . Presence medical condition require regular treatment prescription drug . Use pharmacologic agent know significantly induce inhibit drugmetabolizing enzyme . within 30 day prior dose . Receipt drug part research study within 30 day prior dose . Drug alcohol addition require treatment past 12 month . Donation significant loss whole blood ( 480 ml ) within 30 day plasma within 14 day prior dose . Positive test result drug abuse screen . Tobacco user within 90 day first study dose . Unable , unwilling tolerate multiple venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>